secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001127537-23-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q3 revenue $17.7M record +31% YoY; raises FY2023 guidance to $67-68M
----------------------------------------------------------------------------

- Record worldwide revenue $17.7M (+31% YoY); U.S. revenue $11.8M (+41% YoY).
- Net loss $14.9M ($0.39 EPS) vs $14.2M ($0.38 EPS) in Q3 2022.
- Raised 2023 revenue guidance to $67-68M (prior $64-66M); gross margin ~74%.
- Adjusted EBITDA loss improved to $9.0M from $9.7M YoY.
- Japan MHLW approved Zephyr Valve reimbursement for severe COPD/emphysema.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000042/0001127537-23-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000042/lung-20231030.htm
  HTML page:      https://secwatch.observer/filing/0001127537-23-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer